<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-02-03</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001829802</issuerCik>
        <issuerName>Sensei Biotherapeutics, Inc.</issuerName>
        <issuerTradingSymbol>SNSE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001843544</rptOwnerCik>
            <rptOwnerName>Fjaellskog Marie-Louise</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SENSEI BIOTHERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1405 RESEARCH BLVD, SUITE 125</rptOwnerStreet2>
            <rptOwnerCity>ROCKVILLE</rptOwnerCity>
            <rptOwnerState>MD</rptOwnerState>
            <rptOwnerZipCode>20850</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.22</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-08-04</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>208333</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Twenty-five percent (25%) of the shares subject to the option vest on the first anniversary of the vesting commencement date June 15,2020, and 1/48th of the shares subject to the option vest monthly thereafter over thirty-six (36) months, subject to Reporting Person's continuous service as of each such date.</footnote>
    </footnotes>

    <remarks>Exhibit 24- Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Mark Ballantyne, Attorney-in-Fact</signatureName>
        <signatureDate>2021-02-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
